Enanta Pharmaceuticals will not exercise co-development option for ABT-493
Enanta Pharmaceuticals announced that it has decided not to exercise its co-development option for ABT-493, Enanta’s next-generation protease inhibitor for hepatitis C virus being developed in Enanta’s collaboration with AbbVie. October 20, 2014